14. A method of preparing a crystalline salt of 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate, which comprises:

heating a solution comprising 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate and a pharmaceutically acceptable acid to provide a salt of 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate;

reducing the solubility of the salt in the solution under conditions sufficient to provide a crystalline salt of 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate; and

isolating the crystalline salt.

15. A method of preparing crystalline 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate hydrochloride, which comprises:

heating a solution comprising water, 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate, and p-toluenesulfonic acid monohydrate;

adding an anti-solvent to the solution to provide a mixture;

cooling the mixture; and

isolating crystalline 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate hydrochloride from the mixture.

16. The method of claim 15, wherein the anti-solvent is acetonitrile.

17. ~~A method of lowering intraocular pressure in a patient, which comprises administering~~ Use of the pharmaceutical formulation of claim 13 in the manufacture of a medicament for lowering intraocular pressure in a patient, wherein the medicament is to be administered to the eye of ~~a~~ the patient.

18. ~~A method of treating, managing or preventing a disease or disorder affecting vision (*e.g.*, glaucoma) in a patient, which comprises contacting the eye of the patient with~~ Use of the pharmaceutical formulation of claim 13 in the manufacture of a medicament for treating, managing or preventing a disease or disorder affecting vision (*e.g.*, glaucoma) in a patient, wherein the medicament is to be contacted with the eye of the patient.